Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Effects of Short-Term High-Concentration Formaldehyde Exposure on Respiratory Microecology and Inflammatory Markers in Healthy Adults (FORM-Resp)

keskiviikko 11. marraskuuta 2026 päivittänyt: First Affiliated Hospital of Ningbo University

Prospective Self-Control Study on the Effects of Short-Term High-Concentration Formaldehyde Exposure on Respiratory Microecology and Inflammatory Markers in Healthy Adults

Formaldehyde exposure is common in some occupational environments, including anatomy laboratories, and may affect respiratory health. However, the early biological changes caused by short-term high-concentration formaldehyde exposure remain unclear.

This prospective self-controlled observational study aims to evaluate the effects of short-term high-concentration formaldehyde exposure on respiratory microecology, inflammatory biomarkers, and acute respiratory symptoms in healthy adults. Participants will be monitored before and after formaldehyde exposure, and changes in airway-related biological indicators will be assessed through biological samples and clinical evaluations.

The findings of this study may provide human evidence for exposure control, ventilation improvement, protective measures, and health risk assessment in environments with formaldehyde exposure.

Tutkimuksen yleiskatsaus

Tila

Aktiivinen, ei rekrytointi

Interventio / Hoito

Yksityiskohtainen kuvaus

This is a prospective self-controlled observational study designed to investigate early respiratory biological responses associated with short-term high-concentration formaldehyde exposure in healthy adults.

Participants will be healthy medical students who enter an anatomy laboratory and experience short-term formaldehyde exposure during anatomy training. Each participant will serve as his or her own control. Biological samples and clinical information will be collected at multiple time points, including before exposure (T0), 6 hours after exposure (T1), and 24 hours after exposure (T2).

The study will evaluate changes in respiratory microecological composition, local inflammatory responses, systemic inflammatory and oxidative stress-related biomarkers, and acute irritation symptoms after formaldehyde exposure. Formaldehyde exposure levels, exposure duration, and protective measures will also be recorded to explore the relationship between exposure intensity and biological responses.

At T0, baseline information, respiratory symptoms, induced sputum samples, peripheral blood samples, and other relevant assessments will be collected. During and after exposure, environmental formaldehyde concentrations and exposure-related information will be monitored. At T1 and T2, repeated assessments will be performed, including symptom evaluation, induced sputum collection, peripheral blood collection, inflammatory biomarker detection, and respiratory microecological analysis.

This study aims to provide human-based evidence regarding early respiratory effects of short-term formaldehyde exposure and may contribute to improving ventilation strategies, occupational protection measures, exposure duration control, and health risk assessment in formaldehyde-exposed environments.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

65

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Zhejiang
      • Ningbo, Zhejiang, Kiina, 315211
        • Wang Changlai Building, East Campus, Ningbo University

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 35 vuotta (Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

Healthy adult medical students who attend anatomy laboratory courses involving short-term formaldehyde exposure will be recruited. Participants will undergo prospective self-controlled observation before and after exposure. Changes in respiratory microbiome composition, airway inflammatory biomarkers, systemic inflammatory and oxidative stress indicators, and acute irritation symptoms after formaldehyde exposure will be evaluated.

Kuvaus

Inclusion Criteria:

  • 1: Aged 18-35 years old

    2: The healthy medical students who participated in the anatomy course for the first time had no systematic formaldehyde / formalin occupational or teaching exposure in the past 6 months.

    3: Health examination, and no history of chronic respiratory diseases ( such as asthma, active allergic rhinitis, chronic sinusitis, bronchiectasis, interstitial pulmonary fibrosis, etc. )

    4: There were no acute upper respiratory tract infection, fever, COVID-19 or influenza-like symptoms in the past 4 weeks.

    5: There was no use of antibiotics, glucocorticoids, bronchodilators, and immunomodulatory drugs in the past 4 weeks.

    6: There was no obvious eye, nose, throat irritation or lower respiratory symptoms at baseline, and was able to cooperate with the completion of three induced sputum, two peripheral blood collections and related follow-up evaluations

    7: Voluntary to participate in and sign a written informed consent.

Exclusion Criteria:

  • 1: Have asthma, COPD, bronchiectasis, interstitial lung disease, chronic sinusitis, active allergic rhinitis or other chronic airway inflammatory diseases

    2: Acute upper respiratory tract infection, fever, COVID-19 or influenza-like symptoms, or active allergies / obvious seasonal allergies occurred in the past 4 weeks

    3: Used antibiotics, systemic or inhaled corticosteroids, bronchodilators, immunomodulatory drugs in the past 4 weeks

    4: Current smoking, use of e-cigarettes or hookah, smoking history in the past six months, or obvious high exposure to second-hand smoke in the past four weeks

    5: Exposure to non-daily formaldehyde, formalin or other strong irritant chemicals in the past 4 weeks

    6: Have a clear history of allergy to formaldehyde or other chemicals, or intolerance to hypertonic saline atomization

    7: Pregnant or lactating women

    8: Severe cardiovascular and cerebrovascular diseases, coagulation dysfunction, recent hemoptysis, severe hypertension, recent ophthalmic surgery, epilepsy requiring drug treatment, severe arrhythmia or other conditions not suitable for induced sputum operation

    9: All follow-ups and biological sample collections could not be completed for personal reasons, or researchers considered it inappropriate to continue participating in the study

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Havaintomallit: COHORT
  • Aikanäkymät: RETROSPECTIVE

Kohortit ja interventiot

Ryhmä/Kohortti
Interventio / Hoito
Formaldehyde Exposure Cohort

Healthy adults receiving anatomy laboratory courses were enrolled in this prospective self-controlled observational study. Participants were exposed to short-term formaldehyde released from fixed tissue specimens in the anatomy laboratory and were evaluated before and after exposure.

Short-term high-concentration formaldehyde exposure during anatomy laboratory courses

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change From Baseline in the Shannon Diversity Index of Induced Sputum Microbiota
Aikaikkuna: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The Shannon Diversity Index of induced sputum microbiota will be measured using 16S ribosomal ribonucleic acid gene sequencing. The index evaluates microbial alpha diversity by accounting for both taxon richness and evenness. It has a minimum value of 0 and no fixed maximum value, with higher values indicating greater microbial diversity. Change from baseline will be calculated as the value at each post-exposure time point minus the baseline value.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change From Baseline in the Chao1 Richness Index of Induced Sputum Microbiota
Aikaikkuna: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The Chao1 Richness Index of induced sputum microbiota will be measured using 16S ribosomal ribonucleic acid gene sequencing. The index estimates the number of microbial taxa in a sample. It has a minimum value of 0 and no fixed maximum value, with higher values indicating greater estimated microbial richness. Change from baseline will be calculated as the value at each post-exposure time point minus the baseline value.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
R-Squared Value From Permutational Multivariate Analysis of Variance of Induced Sputum Microbial Community Structure Across Sampling Time Points
Aikaikkuna: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Beta diversity of induced sputum microbiota will be evaluated using principal coordinates analysis and permutational multivariate analysis of variance. The primary reported measure will be the R-squared value from the permutational multivariate analysis of variance, representing the proportion of variation in microbial community structure explained by sampling time. Values range from 0 to 1, with higher values indicating that sampling time explains a greater proportion of variation in microbial community structure.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Induced Sputum Neutrophil Percentage
Aikaikkuna: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of neutrophils in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of neutrophils. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage and reported in percentage points.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Neutrophils in Induced Sputum
Aikaikkuna: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of neutrophils in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of neutrophils. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Macrophages and Monocytes in Induced Sputum
Aikaikkuna: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of macrophages and monocytes in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of macrophages and monocytes. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Lymphocytes in Induced Sputum
Aikaikkuna: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of lymphocytes in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of lymphocytes. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Eosinophils in Induced Sputum
Aikaikkuna: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of eosinophils in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of eosinophils. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Bronchial Epithelial Cells in Induced Sputum
Aikaikkuna: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of bronchial epithelial cells in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of bronchial epithelial cells. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Interleukin 1 Beta Concentration in Induced Sputum Supernatant
Aikaikkuna: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Interleukin 1 beta concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Interleukin 6 Concentration in Induced Sputum Supernatant
Aikaikkuna: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Interleukin 6 concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Interleukin 8 Concentration in Induced Sputum Supernatant
Aikaikkuna: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Interleukin 8 concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Tumor Necrosis Factor Alpha Concentration in Induced Sputum Supernatant
Aikaikkuna: Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Tumor necrosis factor alpha concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in C-Reactive Protein Concentration in Peripheral Blood
Aikaikkuna: Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure

C-reactive protein concentration will be measured in peripheral blood. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration.

Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Interleukin 6 Concentration in Peripheral Blood
Aikaikkuna: Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure

Interleukin 6 concentration will be measured in peripheral blood. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration.

Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Tumor Necrosis Factor Alpha Concentration in Peripheral Blood
Aikaikkuna: Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure

Tumor necrosis factor alpha concentration will be measured in peripheral blood. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration.

Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Malondialdehyde Concentration in Peripheral Blood
Aikaikkuna: Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure

Malondialdehyde concentration will be measured in peripheral blood as a marker of oxidative stress. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration.

Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Eye Irritation Score Assessed Using a Visual Analog Scale
Aikaikkuna: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Eye irritation will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Nasal Irritation Score Assessed Using a Visual Analog Scale
Aikaikkuna: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Nasal irritation will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Throat Irritation Score Assessed Using a Visual Analog Scale
Aikaikkuna: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Throat irritation will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Cough Score Assessed Using a Visual Analog Scale
Aikaikkuna: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Cough will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Chest Tightness Score Assessed Using a Visual Analog Scale
Aikaikkuna: Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Chest tightness will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Chao Cao, Ningbo University Affiliated First Hospital

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Sunnuntai 11. lokakuuta 2026

Ensisijainen valmistuminen (Todellinen)

Sunnuntai 1. marraskuuta 2026

Opintojen valmistuminen (Arvioitu)

Keskiviikko 30. kesäkuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 14. syyskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 11. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Tiistai 17. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 17. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 11. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • 2026-R311-01

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

PÄÄTTÄMÄTÖN

IPD-suunnitelman kuvaus

The plan for sharing individual participant data (IPD) has not yet been determined. Any future data sharing will be considered in accordance with ethical requirements, participant privacy protection, and institutional policies.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa